SCHEMBL6210503

SCHEMBL6210503

Fc1cnc(Nc2ccc3ncccc3c2)nc1NCc1ccccn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 9/20 0.54
PTK2B Q14289 7/20 0.54
ULK1 O75385 1/20 0.49
ULK2 Q8IYT8 1/20 0.49
SYK P43405 4/20 0.46
AURKA O14965 2/20 0.44
CDK1 P06493 2/20 0.44
JAK3 P52333 2/20 0.44
PLK4 O00444 1/20 0.44
PDPK1 O15530 1/20 0.44
JAK2 O60674 1/20 0.44
PRKD3 O94806 1/20 0.44
MAP4K4 O95819 1/20 0.44
NTRK1 P04629 1/20 0.44
INSR P06213 1/20 0.44
LCK P06239 1/20 0.44
FYN P06241 1/20 0.44
FES P07332 1/20 0.44
CSF1R P07333 1/20 0.44
LYN P07948 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6214553 0.87 PTK2 (0.62) PTK2PTK2BULK1ULK2SYK
SCHEMBL6213528 0.82 PTK2 (0.78) PTK2PTK2BULK1SYKCDK1
SCHEMBL14923949 0.78 SYK (0.49) SYKAURKAJAK3RPS6KB1MAPK8
SCHEMBL7258541 0.78 SYK (0.58) PTK2PTK2BULK1ULK2SYK
SCHEMBL6211846 0.77 EGFR (0.53) PTK2PTK2BULK1ULK2SYK
SCHEMBL6209171 0.77 PTK2 (0.80) PTK2PTK2BULK1AURKACDK1
SCHEMBL7258580 0.76 SYK (0.52) PTK2PTK2BULK1ULK2SYK
SCHEMBL657592 0.76 SYK (0.76) SYKAURKAMAPK8AURKB
SCHEMBL7258709 0.75 KDR (0.54) PTK2PTK2BULK1ULK2SYK
SCHEMBL3448838 0.75 PTK2 (0.60) PTK2PTK2BCDK1IGF1RFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP claimed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US claimed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO claimed
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP disclosed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US disclosed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220177-A1 Compound for the treatment of abnormal cell growth CCNA1, CCNB1, CCNT1 PTK2 3004/4885PTK2B 1941/4885ULK1 4689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.